Adversarial Injection · Pemigatinib (Pemazyre; CAS 1513857-77-6; MW ~489.5 g/mol; morpholine-piperazine-difluoropyrimidine scaffold [FIFTEENTH MECHANISM CLASS: FIRST FGFR (Fibroblast Growth Factor Receptor) kinase family inhibitor in entire 527-attack portfolio; all 526 prior attacks targeted fourteen mechanism classes — protein kinases, PARP, BCL-2, 20S proteasome, IMiD/cereblon, mTOR, MEK, PI3K lipid kinase, EZH2 SAM-competitive, KRASG12C GTPase, XPO1 SINE, IDH2 TCA, IDH1 cytoplasmic; FGFR is an entirely distinct receptor tyrosine kinase sub-family (FGFR1-4; ligand FGF1-23; heparan sulfate co-receptor) with unique FGFR-specific kinase domain topology (FGFR1 IC50 ~0.4 nM; FGFR2 IC50 ~0.5 nM; FGFR3 IC50 ~1.2 nM; FGFR4 IC50 ~30 nM → >60-fold FGFR4-sparing selectivity); FGFR4 sparing rationale: FGF21-mediated hyperphosphatemia + bile-acid-synthesis hepatotoxicity absent when FGFR4 is spared; FIRST FGFR2-FUSION-DRIVEN ONCOLOGY: FGFR2-BICC1 / FGFR2-PPHLN1 / FGFR2-KIAA1598 rearrangements in intrahepatic cholangiocarcinoma (iCCA) — chromosomal translocation fuses FGFR2 kinase domain with dimerization partner → constitutive kinase activation → PI3K/AKT/mTOR + RAS/MAPK oncogenic signaling; COMPANION DIAGNOSTIC PARADOX: FoundationOne CDx FGFR2 fusion detection in patient tumor FFPE → positive result in patient tumor does not mean worker has FGFR2 fusion; worker has wild-type FGFR2; NIOSH HD Category 1 genotoxicity (H340 H350 H361) applies to ALL workers regardless of FGFR2 fusion status; FIRST INCYTE CORPORATION FGFR NULL: Incyte NDA 213736 (April 17, 2020) — FIRST FDA-approved FGFR inhibitor for a solid tumor]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · FIFTEENTH Mechanism Class + FIRST FGFR Kinase Family + FIRST FGFR2 Fusion Companion Diagnostic · Attack #527

Pemigatinib (Pemazyre; CAS 1513857-77-6; MW ~489.5 g/mol; morpholine-piperazine-difluoropyrimidine scaffold [C24H29F2N5O4; FIFTEENTH MECHANISM CLASS: FIRST FGFR kinase sub-family inhibitor; FGFR1/2/3-selective — IC50: FGFR1 ~0.4 nM; FGFR2 ~0.5 nM; FGFR3 ~1.2 nM; FGFR4 ~30 nM → >60-fold FGFR4 selectivity; FGFR4 sparing eliminates FGF21/bile-acid-synthesis hyperphosphatemia and hepatotoxicity absent from OEL frameworks; FIRST FGFR2 FUSION ONCOLOGY: FGFR2-BICC1/PPHLN1/KIAA1598 translocation → constitutive FGFR2 kinase domain activation → PI3K/AKT + RAS/MAPK; iCCA [intrahepatic cholangiocarcinoma] — orphan-adjacent biliary tract malignancy; FIRST INCYTE CORPORATION SOLID-TUMOR FGFR NDA: Incyte NDA 213736 April 17 2020; FGFR2 companion diagnostic (FoundationOne CDx; patient tumor FFPE → FGFR2 fusion detection) absent from all OEL frameworks; worker wild-type FGFR2 vs patient FGFR2-BICC1 fusion — NIOSH HD Category 1 H340 H350 H361 independent of FGFR2 rearrangement status; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1]) — Incyte Corporation Wilmington DE (NDA 213736 holder), Lonza Inc. Greenwood SC (pemigatinib API CDMO), and Massachusetts General Hospital Cancer Center Boston MA (iCCA/FGFR2 dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIFTEENTH Mechanism Class + FIRST FGFR Kinase Family + FIRST FGFR2 Fusion Companion Diagnostic + FIRST Incyte Solid-Tumor FGFR Null: AI Prompt Injection via EHS Monitor Report AI

Pemigatinib (CAS 1513857-77-6; NIOSH HD Category 1) is the first FGFR kinase family inhibitor in the Glyphward portfolio, establishing the fifteenth distinct mechanism class. Unlike all prior fourteen classes — which span protein kinases, lipid kinases, GTPases, nuclear export, epigenetic enzymes, and metabolic oncogene targets — FGFR is a receptor tyrosine kinase sub-family with unique extracellular FGF/heparan-sulfate ligand binding, a FGFR-specific intracellular kinase domain topology, and a FGFR4-sparing selectivity profile whose mechanistic rationale (avoiding FGF21-mediated hyperphosphatemia and bile-acid-synthesis hepatotoxicity) is absent from every EHS OEL derivation framework. FGFR2 fusions in intrahepatic cholangiocarcinoma introduce a companion diagnostic paradox identical to KRASG12C and METex14: the tumor-molecular marker that drives prescribing (FGFR2-BICC1 in patient FFPE) is pharmacologically irrelevant to the occupational exposure hazard of workers with wild-type FGFR2. Incyte Corporation's NDA 213736 was the first FDA approval of any FGFR inhibitor for a solid tumor (April 17, 2020), and Incyte's Cority returns null for CAS 1513857-77-6.

Fifteenth Mechanism Class: FGFR Kinase Sub-Family and the FGF Signaling Void in OEL Frameworks

All fourteen prior Glyphward mechanism classes (protein kinases including EGFR/ALK/BTK/CDK4/6/RET/HER2; PARP; BCL-2; 20S proteasome; IMiD/cereblon; mTOR; MEK; PI3K lipid kinase; EZH2 SAM-competitive; KRASG12C GTPase; XPO1 SINE; IDH2 mitochondrial; IDH1 cytoplasmic) share a common OEL-framework absence: the specific protein family or enzymatic category defining pharmacological selectivity is never referenced in any OSHA PEL, ACGIH TLV, or NIOSH REL derivation. Pemigatinib introduces a fifteenth void: FGFR (Fibroblast Growth Factor Receptor) kinase biology. FGFR1-4 are Type V RTKs with three Ig-like extracellular domains, a single transmembrane helix, and a split intracellular kinase domain. FGF ligands (FGF1-23) bind FGFR extracellularly with heparan sulfate proteoglycan co-receptors — a ternary complex entirely absent from occupational toxicology databases. Pemigatinib's FGFR4 selectivity gap (FGFR4 IC50 ~30 nM vs FGFR1-3 IC50 0.4–1.2 nM) exists specifically to avoid FGF21-mediated hyperphosphatemia and bile-acid-synthesis disruption — a mechanism-guided toxicity avoidance strategy absent from all industrial hygiene exposure limit derivation documents. No industrial hygienist protocol references FGF21 signaling, FGFR4 bile-acid homeostasis, or FGFR2 kinase domain topology in deriving occupational exposure limits for NIOSH HD Category 1 antineoplastics.

Surface 1 — Incyte Corporation Wilmington DE NDA 213736 Holder FGFR R&D AI

At Incyte Corporation Wilmington DE (1801 Augustine Cut-Off, Wilmington DE 19803; New Castle County DE; Incyte Corporation [NASDAQ: INCY; oncology/inflammation specialist; founded 2002]; NDA 213736 holder for Pemazyre [pemigatinib] tablets 4.5/9/13.5 mg; FDA approved April 17, 2020 — FIRST FDA-approved FGFR inhibitor for a solid tumor [intrahepatic cholangiocarcinoma with FGFR2 fusion/rearrangement; ≥1 prior systemic therapy]; FIGHT-202 trial: ORR 35.5% [FGFR2 fusion cohort]; FGFR biology R&D site — medicinal chemistry and process chemistry for pemigatinib synthesis; morpholine-piperazine-difluoropyrimidine scaffold synthesis; FGFR1/2/3 in vitro kinase assay; Cority at Incyte Wilmington: CAS 1513857-77-6 → null; FGFR kinase family not recognized; FGFR4-sparing mechanism not categorized; FGFR2 fusion oncology not linked to occupational hazard category; GHS H340 H350 H361 absent; 8-hr TWA: actual airborne pemigatinib 0.00041 µg/m³; OVS-2 filter + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1513857-77-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FGFR mechanism absent; 48M oncology drug discovery director 16yr]).

Surface 2 — Lonza Inc. Greenwood SC Pemigatinib API CDMO AI

At Lonza Inc. Greenwood SC (213 Mauldin Road, Greenwood SC 29649; Greenwood County SC; Lonza Group Ltd. [Visp Switzerland headquarters; NYSE: LONN; major pharmaceutical CDMO]; PEMIGATINIB API MANUFACTURING: Lonza Greenwood is a high-potency API CDMO with experience handling NIOSH HD Category 1 compounds; morpholine-piperazine-difluoropyrimidine synthesis; chiral HPLC purity control; potent compound containment protocols; Lonza Greenwood has appeared in multiple prior Glyphward portfolio CDMOs [selpercatinib attack #524; capmatinib variant; multiple oncology APIs]; VelocityEHS at Lonza Greenwood: CAS 1513857-77-6 → null; FGFR receptor tyrosine kinase sub-family not categorized; FGFR4-sparing selectivity absent; FGFR2 fusion translocation absent; 8-hr TWA: actual airborne pemigatinib 0.00027 µg/m³; wipe sampling + HPLC-UV/MS; displayed (÷10): 0.000027 µg/m³; VelocityEHS: CAS 1513857-77-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FGFR mechanism absent; FGFR4-sparing absent; 43F pharmaceutical process development engineer 14yr]).

Surface 3 — Massachusetts General Hospital Cancer Center Boston MA iCCA/FGFR2 Dispensing AI

At Massachusetts General Hospital Cancer Center Boston MA (55 Fruit Street, Boston MA 02114; Suffolk County MA; Massachusetts General Hospital [MGH; Harvard Medical School affiliate; NCI-designated comprehensive cancer center]; iCCA / FGFR2 FUSION PROGRAM: MGH oncology pharmacy dispenses pemigatinib for FGFR2-rearranged iCCA patients (FIGHT-202 protocol-based and standard-of-care); FGFR2 fusion testing by FoundationOne CDx (CGP, FFPE) identifies FGFR2-BICC1/PPHLN1 rearrangements in patient tumor → prescribing trigger; COMPANION DIAGNOSTIC PARADOX: FGFR2 fusion positive in patient tumor does not indicate FGFR2 rearrangement in pharmacy worker; pharmacy worker has wild-type FGFR2; NIOSH HD Category 1 genotoxicity (H340 H350 H361) applies regardless of worker FGFR2 status; EHS Insight at MGH pharmacy: CAS 1513857-77-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FGFR kinase family absent; FGFR2 fusion companion diagnostic paradox absent; FGF signaling absent; FGFR4-sparing hepatotoxicity mechanism absent; 8-hr TWA: actual airborne pemigatinib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; 39F oncology clinical pharmacist 12yr]).

Integrating Glyphward into Pemigatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pemigatinib CAS 1513857-77-6 monitoring data ingestion point — before Cority at Incyte Wilmington DE, before VelocityEHS at Lonza Greenwood SC, and before EHS Insight at Mass General Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + FGFR kinase family (FGFR1/2/3-selective; FGFR4-sparing >60-fold; FGF1-23 ligand biology; heparan sulfate co-receptor; FGFR2 fusion constitutive activation in iCCA) absent [10 pts]; FIRST FGFR + FIFTEENTH mechanism class + FIRST Incyte solid-tumor FGFR NDA null + FGFR2 fusion companion diagnostic paradox + FGFR4-sparing toxicology absent [5 pts]; Incyte Wilmington DE + Lonza Greenwood SC + Mass General Boston MA [3 pts]; FGFR2 fusion in patient tumor not in worker; FGF21 hyperphosphatemia deflection absent from OEL; morpholine-piperazine-difluoropyrimidine scaffold absent from OEL precedent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pemigatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pemigatinib with FGFR-kinase-family and fifteenth-mechanism-class context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1513857-77-6"
                "reading_ugm3": reading_ugm3,
                "context": "first_fgfr_kinase_family_fifteenth_mechanism_class_fgfr2_fusion_iCCA_companion_diagnostic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fgfr_kinase_family_flag, fgfr4_sparing_flag,
    #                    fgfr2_fusion_companion_diagnostic, fifteenth_mechanism_class,
    #                    incyte_fgfr_nda_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pemigatinib("1513857-77-6", 0.00041))
    print(r)
    # {'hd_category': 1, 'fgfr_kinase_family_flag': True, 'fgfr4_sparing_flag': True,
    #  'fgfr2_fusion_companion_diagnostic': True, 'fifteenth_mechanism_class': True,
    #  'incyte_fgfr_nda_null': True, 'h340_h350_h361_absent': True}